Octanate (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor replacement therapy presented as an intravenous solution for intravenous use. It treats hemophilia A in patients requiring factor VIII replacement. GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Octanate is used in the management of inherited bleeding disorders that involve the coagulation cascade, particularly hemophilia A.

- Hemophilia A (severe): Provides factor VIII replacement to prevent or control bleeding episodes. - Hemophilia A (moderate): Supports routine prophylaxis to reduce frequency of bleeds. - Hemophilia A (mild) and other factor VIII deficiencies: Supplies the missing factor VIII to achieve hemostasis. - Surgical prophylaxis: Enables safe surgical procedures by correcting factor VIII levels. - Acute bleeding episodes: Restores the coagulation cascade to manage acute bleeds in patients with hemophilia A.

Octanate   …  … … .... ... ... ... ... ... ... … … … … … ... ... … ... …  … ...